COI.
search Request for Consideration arrow_forward menu
close Submit Innovation
close
92
London, UK Alphabet Subsidiary

Generative AI for Protein-Drug Design

Isomorphic Labs • Led by ["Demis Hassabis"]

🔒 Confidential
COI SCORE 92 VERIFIED

🔬 The Innovation Core

The Pain Point

Knowing a protein's structure (AlphaFold) is only step one. The harder step is designing a chemical that binds to it effectively, which currently involves years of trial-and-error chemistry.

The Solution

An 'AI-First' drug design engine built on top of AlphaFold 3. It moves beyond static structure prediction to dynamic 'protein-ligand' interaction modeling, generating novel chemical matter that is optimized for binding affinity and toxicity in silico.

⚡ Verified Impact

● Validated
CERTIFICATION

Prototype

TRL 6/9

📊 Market Traction

Revenue History ($M)

Market Share

🧠 Analyst Verdict: Deep Tech Frontier

"Spinning out of DeepMind gives Isomorphic an unfair advantage: exclusive access to the latest AlphaFold iterations before the public. Their $3B+ in deal value with Lilly and Novartis signals that big pharma views them as the premier partner for 'difficult' targets."

✅ Pros

  • ["AlphaFold Heritage: Unrivaled access to the world's best protein structure models (DeepMind).","Talent Density: Attracts top talent from both Google Research and pharma.","Deal Economics: Secured high upfronts ($45M from Lilly) for a company with no clinical assets."]

⚠️ Risks

  • ["Black Box: Highly secretive about internal pipeline vs partner programs.","Commercial Pressure: High expectations to deliver 'miracle' results to justify Alphabet's investment."]

🛠️ Use Cases

Market Maturity

Stop Guessing.
Know What's Deployable.

Marketing brochures look the same for TRL-3 (Concept) and TRL-9 (Proven) tech. Our radar cuts through the noise, showing you exactly if this innovation has crossed the "Pilot-to-Production" chasm.

9

Commercial Grade

Fully audited operational history. Ready for scale.

6

Prototype / Pilot

Functional in relevant environments. High risk, high reward.

Current Maturity Status

TRL Score 6.0 / 9.0
  • check_circle Technology validated in lab (TRL 4)
  • check_circle System prototype demonstration (TRL 7)
  • pending Operational Verification (In Progress)
Transparency

Forensic Evidence Chain

We don't just "approve" listings. We build a permanent, immutable audit trail for every verified claim. See exactly what was checked, when, and by whom.

View Sample Audit Report →

Technical Diligence

> Architecture Review: PASS
> Security Audit: ISO 27001
> Scalability Test: 10k TPS

Customer Verification

> Client Interview: #8821
> Deployment Status: LIVE
> ROI Confirmed: 18% Savings

Certification Issued

STATUS: VERIFIED verified

Enterprise Action Center

Select the engagement model that fits your business needs.

🚀
Launch Pilot / POC
Submit your problem statement and request a proof of concept scope.
💡
Propose Use Case
Have a new application for this tech? Submit a use case for review.
⭐
Submit Review
Already using this solution? Verify impact and submit your CSAT score.
🛡️
Request Due Diligence
Access compliance certs, security audits, and financial health reports.

Secure Premium Access

Complete to proceed with your request